TORONTO, April 25 /CNW/ - Biosign Technologies Inc.(TSXV: BIO) ("Biosign") announces the appointment of Colley Clarke as interim Chief Financial
Officer (CFO). Mr. Clarke is known for his financial leadership of TSX
Venture Exchange and NASDAQ listed companies in the technology, media
and communications industries. He will oversee Biosign's finance,
accounting and investor relations functions, while focusing on the
company's growth and profitability. Reporting to President and CEO, Dr.
Radu Leca, Mr. Clarke will be involved in strategic planning,
operations and executive recruiting.
"Colley is an accomplished executive with international experience in
finance, capital markets, corporate strategy, operations management,
investor relations, legal and human resources," stated Radu Leca. "We
are confident that he will help us accomplish our mission of becoming a
leader in global health monitoring."
Mr. Clarke has served as CFO of Redknee Solutions Inc. (TSX: RKN), The
Descartes Systems Group Inc. (Nasdaq, TSX: DSG), BCE Media, Canadian
Satellite Communications Inc. and WPP Group Plc. Mr. Clarke currently
serves as the Chairman of the Board and Chair of the Audit Committee
for the Edleun Group, Inc. (TSXV: EDU). He is a Chartered Accountant,
with an MBA from the Ivey School of Business in London.
Mr. Clarke succeeds Scott Worthington, who has decided to leave the
company following the departure of Chief Executive Peter Tassiopoulos
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign Contact Information
| || |
| Radu Leca |
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
| || Alan S. Roemer, SVP |
The Trout Group LLC
Phone: 646 378-2900